Business Description
Matinas BioPharma Holdings Inc
NAICS : 325412
SIC : 2834
ISIN : US5768101058
Description
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.87 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.19 | |||||
| Debt-to-EBITDA | -0.16 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -7.48 | |||||
| Beneish M-Score | -4.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 71 | |||||
| 3-Year EBITDA Growth Rate | 4.1 | |||||
| 3-Year EPS without NRI Growth Rate | 3.6 | |||||
| 3-Year FCF Growth Rate | 6.9 | |||||
| 3-Year Book Growth Rate | -33.2 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 20.83 | |||||
| 9-Day RSI | 30.46 | |||||
| 14-Day RSI | 36.23 | |||||
| 6-1 Month Momentum % | 38.93 | |||||
| 12-1 Month Momentum % | -59.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.93 | |||||
| Quick Ratio | 5.93 | |||||
| Cash Ratio | 5.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.8 | |||||
| Shareholder Yield % | 1.24 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -2168.43 | |||||
| Net Margin % | -2093.25 | |||||
| FCF Margin % | -1393.98 | |||||
| ROE % | -82.22 | |||||
| ROA % | -66.69 | |||||
| ROIC % | -203.15 | |||||
| ROC (Joel Greenblatt) % | -382.58 | |||||
| ROCE % | -75.51 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 36.49 | |||||
| PB Ratio | 2.02 | |||||
| Price-to-Tangible-Book | 2.59 | |||||
| EV-to-EBIT | -1.49 | |||||
| EV-to-EBITDA | -1.55 | |||||
| EV-to-Revenue | 32.3 | |||||
| EV-to-Forward-Revenue | 18.66 | |||||
| EV-to-FCF | -2.32 | |||||
| Price-to-Net-Current-Asset-Value | 4.54 | |||||
| Price-to-Net-Cash | 4.54 | |||||
| Earnings Yield (Greenblatt) % | -67.11 | |||||
| FCF Yield % | -33.56 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:MTNB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Matinas BioPharma Holdings Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.096 | ||
| EPS (TTM) ($) | -0.12 | ||
| Beta | 0.87 | ||
| Volatility % | 110.28 | ||
| 14-Day RSI | 36.23 | ||
| 14-Day ATR ($) | 0.023816 | ||
| 20-Day SMA ($) | 0.22458 | ||
| 12-1 Month Momentum % | -59.77 | ||
| 52-Week Range ($) | 0.1103 - 0.89 | ||
| Shares Outstanding (Mil) | 250.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Matinas BioPharma Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Matinas BioPharma Holdings Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Matinas BioPharma Holdings Inc Frequently Asked Questions
What is Matinas BioPharma Holdings Inc(MTNB)'s stock price today?
The current price of MTNB is $0.18. The 52 week high of MTNB is $0.89 and 52 week low is $0.11.
When is next earnings date of Matinas BioPharma Holdings Inc(MTNB)?
The next earnings date of Matinas BioPharma Holdings Inc(MTNB) is 2024-05-10 Est..
Does Matinas BioPharma Holdings Inc(MTNB) pay dividends? If so, how much?
Matinas BioPharma Holdings Inc(MTNB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers